Jing-Zhou Hou1, Kellie Ryan2, Senxi Du3, Bruno Fang4, Stanley Marks1, Ray Page5,6, Eileen Peng4, Keith Szymanski7, Sharon Winters1, Hannah Le2. 1. University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA 15232, USA. 2. US Medical Affairs, AstraZeneca, Gaithersburg, MD 20878, USA. 3. Keck School of Medicine, Los Angeles, CA 90033, USA. 4. Regional Cancer Care Associates, East Brunswick, NJ 08816, USA. 5. The Center of Cancer & Blood Disorders, Fort Worth, TX 76104, USA. 6. Quality Cancer Care Alliance Network, Tacoma, WA 98405, USA. 7. US Market Access, AstraZeneca, Gaithersburg, MD 20878, USA.
Abstract
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.
Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.
Authors: Gellért Balázs Karvaly; István Vincze; Alexandra Balogh; Zoltán Köllő; Csaba Bödör; Barna Vásárhelyi Journal: Molecules Date: 2022-07-25 Impact factor: 4.927